Evidence map›Paper›PMID 35205765›Full record

ArticleCancers2022

Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.

Sofia Genta, Guido Ghilardi, Luciano Cascione, Darius Juskevicius, Alexandar Tzankov, Sämi Schär, Lisa Milan, Maria Cristina Pirosa, Fabiana Esposito, Teresa Ruberto and 6 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00544219 (Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00544219 nacompletednot on this map

Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study

TypeinterventionalSponsorSwiss Cancer InstituteRan2007 to 2016Enrolled156ConditionsLymphomaArmsrituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Association of [Diagnostics (Basel, Switzerland) · 2025
    Article
  3. Clinical scoring systems, molecular subtypes and baseline [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Review
  4. Prognostic value of interimAnnals of hematology · 2023
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Sofia GentaClinic of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Guido GhilardiClinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.ORCID 0000-0002-0095-3579
Luciano CascioneInstitute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.ORCID 0000-0002-4606-0637
Darius JuskeviciusInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.ORCID 0000-0002-1413-921X
Alexandar TzankovInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.ORCID 0000-0002-1100-3819
Sämi SchärSwiss Group for Clinical Cancer Research (SAKK) Coordinating Center, 3008 Bern, Switzerland.
Lisa MilanClinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Maria Cristina PirosaClinic of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Fabiana EspositoClinic of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Teresa RubertoClinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Luca GiovanellaClinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.ORCID 0000-0003-0230-0974
Stefanie HayozSwiss Group for Clinical Cancer Research (SAKK) Coordinating Center, 3008 Bern, Switzerland.
Christoph MamotDivision of Oncology, Cantonal Hospital Aarau, 5001 Aarau, Switzerland.ORCID 0000-0002-8838-6360
Stefan DirnhoferInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Emanuele ZuccaClinic of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.ORCID 0000-0002-5522-6109
Luca CerianiInstitute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.ORCID 0000-0002-6371-097X
Ente Ospedaliero Cantonale · CHUniversity of Basel · CHSwiss Group For Clinical Cancer Research · CHKantonsspital Aarau · CHSIB Swiss Institute of Bioinformatics · CHUniversity of Bern · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate estimation of the progression risk after first-line therapy represents an unmet clinical need in diffuse large B-cell lymphoma (DLBCL). Baseline (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) parameters, together with genetic analysis of lymphoma cells, could refine the prediction of treatment failure. We evaluated the combined impact of mutation profiling and baseline PET/CT functional parameters on the outcome of DLBCL patients treated with the R-CHOP14 regimen in the SAKK38/07 clinical trial (NCT00544219). The concomitant presence of mutated

Indexed as

DLBCLlymphomamutational profilePET/CTprognostic index

Identifiers

PMID35205765
PMCPMC8870624
OpenAlexW4213354195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.